Otezla 30 mg tablet NDC 59572-0631-06 30 days supply
Lack of Processing Controls.
18,003 recalls, newest first
Lack of Processing Controls.
Lack of Processing Controls.
Lack of Processing Controls.
Lack of Processing Controls.
Lack of Processing Controls.
Lack of Processing Controls.
Lack of Processing Controls.
CGMP Deviations: finished products were manufactured with poor quality water.
CGMP Deviations: finished products were manufactured with poor quality water.
Failed Dissolution Specifications
Microbial Contamination of Non-Sterile Products
CGMP Deviations: the product was produced with substandard GMP manufacturing processes.
Subpotent Drug: Product crystallization with accompanying low out of specification results for chlorhexidine assay.
Subpotent Drug: Product crystallization with accompanying low out of specification results for chlorhexidine assay.
Subpotent Drug: Product crystallization with accompanying low out of specification results for chlorhexidine assay.
cGMP Deviations
cGMP Deviations
cGMP Deviations
Lack of Assurance of Sterility; confirmed customer report of a leaking bags and mold found between the outer bag and the overwrap
Lack of Assurance of Sterility; confirmed customer report of a leaking bags and mold found between the outer bag and the overwrap
Lack of Assurance of Sterility; confirmed customer report of a leaking bags and mold found between the outer bag and the overwrap
Lack of Assurance of Sterility; confirmed customer report of a leaking bags and mold found between the outer bag and the overwrap
Lack of Assurance of Sterility; confirmed customer report of a leaking bags and mold found between the outer bag and the overwrap
Lack of Assurance of Sterility; confirmed customer report of a leaking bags and mold found between the outer bag and the overwrap
Lack of Assurance of Sterility; confirmed customer report of a leaking bags and mold found between the outer bag and the overwrap